Cleared Traditional

K221112 - CARTO 3 EP Navigation System with Advanced Focus Mapping (AFM)

K221112 is an FDA 510(k) clearance for CARTO 3 EP Navigation System with Advan..., manufactured by Biosense Webster, Inc.. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Traditional 510(k) pathway after a 124-day FDA review.

K221112 · Biosense Webster, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2022
Decision
124d
Days
Class 2
Risk

K221112 is an FDA 510(k) clearance for the CARTO 3 EP Navigation System with Advanced Focus Mapping (AFM). Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Biosense Webster, Inc. (Irvine, US). The FDA issued a Cleared decision on August 17, 2022 after a review of 124 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Biosense Webster, Inc. devices

FDA 510(k) Submission Details - K221112

510(k) Number K221112 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 15, 2022
Decision Date August 17, 2022
Days to Decision 124 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
1d faster than avg
Panel avg: 125d · This submission: 124d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 359
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K221112.
KODEX – EPD™ System 1.5.0
K212493 · Philips Medical Systems Nederland, B.V. (Pmsn) · Oct 2022
AcQMap High Resolution Imaging and Mapping System
K222209 · Acutus Medical, Inc. · Oct 2022
EnSite X EP System
K221213 · Abbott · Aug 2022
DeepRhythmAI
K210822 · Medicalgorithmics S.A. · Jul 2022
ZEUS System (Zio Watch)
K213409 · iRhythm Technologies, Inc. · Jul 2022
AcQMap High Resolution Imaging and Mapping System
K220784 · Acutus Medical, Inc. · Jul 2022